HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation

Oncogene

Volumn 31, Issue 10, 2012, Pages 1299-1310

  Haapa Paananen, S ^a   Kiviluoto, S ^a   Waltari, M ^b   Puputti, M ^b   Mpindi, J P ^a,b   Kohonen, P ^a   Tynninen, O ^c   Haapasalo, H ^d   Joensuu, H ^b   Perala M ^a   Kallioniemi, O ^a,b  

^a TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

astrocytoma; glioblastoma; glioma; HES6; RNAi; TMA

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 6; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA CELL; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE SILENCING; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE DOSAGE; GENES, MYC; GLIOMA; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84858007295     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.316     Document Type: Article

References (39)

1. Bae S, Bessho Y, Hojo M, Kageyama R. (2000). The bHLH gene Hes6, an inhibitor of Hes1, promotes neuronal differentiation. Development 127: 2933-2943. (Pubitemid 30487611)
2. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
3. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T et al. (2010). The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 5: e12548.
4. Cossins J, Vernon AE, Zhang Y, Philpott A, Jones PH. (2002). Hes6 regulates myogenic differentiation. Development 129: 2195-2207. (Pubitemid 34874232)
5. Eun B, Cho B, Moon Y, Kim SY, Kim K, Kim H et al. (2010). Induction of neuronal apoptosis by expression of Hes6 via p53-dependent pathway. Brain Res 1313: 1-8.
6. Eun B, Lee Y, Hong S, Kim J, Lee HW, Kim K et al. (2008). Hes6 controls cell proliferation via interaction with cAMP-response element-binding protein-binding protein in the promyelocytic leukemia nuclear body. J Biol Chem 283: 5939-5949.
7. Gratton MO, Torban E, Jasmin SB, Theriault FM, German MS, Stifani S. (2003). Hes6 promotes cortical neurogenesis and inhibits Hes1 transcription repression activity by multiple mechanisms. Mol Cell Biol 23: 6922-6935. (Pubitemid 37214660)
8. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK et al. (2006). Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12: 473-477. (Pubitemid 43166138)
9. Hartman J, Lam EW, Gustafsson JA, Strom A. (2009). Hes-6, an inhibitor of hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation. Breast Cancer Res 11: R79.
10. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. (2006). RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22: 2825-2827. (Pubitemid 44742407)
11. Illi B, Puri P, Morgante L, Capogrossi MC, Gaetano C. (2000). Nuclear factor-kappaB and cAMP response element binding protein mediate opposite transcriptional effects on the flk-1/KDR gene promoter. Circ Res 86: E110-E117.
12. Jennings BH, Tyler DM, Bray SJ. (1999). Target specificities of drosophila enhancer of split basic helix-loop-helix proteins. Mol Cell Biol 19: 4600-4610. (Pubitemid 29289498)
13. Jhas S, Ciura S, Belanger-Jasmin S, Dong Z, Llamosas E, Theriault FM et al. (2006). Hes6 inhibits astrocyte differentiation and promotes neurogenesis through different mechanisms. J Neurosci 26: 11061-11071. (Pubitemid 44772196)
14. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. (2005). Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 207: 224-231. (Pubitemid 41404153)
15. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H et al. (2008). Systematic bioinformatic analysis of expression levels of 17 330 human genes across 9 783 samples from 175 types of healthy and pathological tissues. Genome Biol 9: R139.
16. Koyano-Nakagawa N, Kim J, Anderson D, Kintner C. (2000). Hes6 acts in a positive feedback loop with the neurogenins to promote neuronal differentiation. Development 127: 4203-4216.
17. Kumar HR, Zhong X, Sandoval JA, Hickey RJ, Malkas LH. (2008). Applications of emerging molecular technologies in glioblastoma multiforme. Expert Rev Neurother 8: 1497-1506.
18. Lassman AB, Dai C, Fuller GN, Vickers AJ, Holland EC. (2004). Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated ras and akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol 1: 157-163.
19. Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA, Buetow K. (2009). Rembrandt: Helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 7: 157-167.
20. Margolin AA, Palomero T, Sumazin P, Califano A, Ferrando AA, Stolovitzky G. (2009). ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenes. Proc Natl Acad Sci U S A 106: 244-249.
21. Mpindi JP, Sara H, Haapa-Paananen S, Kilpinen S, Pisto T, Bucher E et al. (2011). GTI: A novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets. PLoS One 6: e17259.
22. Naumann U, Maass P, Gleske AK, Aulwurm S, Weller M, Eisele G. (2008). Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. Int J Oncol 33: 759-765.
23. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
24. Ohgaki H, Kleihues P. (2009). Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100: 2235-2241.
25. Ohgaki H, Kleihues P. (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453. (Pubitemid 47339290)
26. Ovaska K, Laakso M, Haapa-Paananen S, Louhimo R, Chen P, Aittomaki V et al. (2010). Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med 2: 65.
27. Panicker SP, Raychaudhuri B, Sharma P, Tipps R, Mazumdar T, Mal AK et al. (2010). p300- and myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget 1: 289-303.
28. Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, Isola J et al. (2006). Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 4: 927-934. (Pubitemid 46121551)
29. Schiffer D, Annovazzi L, Caldera V, Mellai M. (2010). On the origin and growth of gliomas. Anticancer Res 30: 1977-1998.
30. Sihto H, Tynninen O, Halonen M, Puputti M, Karjalainen-Lindsberg ML, Kukko H et al. (2009). Tumour microvessel endothelial cell KIT and stem cell factor expression in human solid tumours. Histopathology 55: 544-553.
31. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S et al. (2005). Upregulation of ASCL1 and inhibition of notch signaling pathway characterize progressive astrocytoma. Oncogene 24: 7073-7083. (Pubitemid 41573636)
32. Strojnik T, Rosland GV, Sakariassen PO, Kavalar R, Lah T. (2007). Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: Correlation of nestin with prognosis of patient survival. Surg Neurol 68: 133-143. (Pubitemid 47087905)
33. Swearingen ML, Sun D, Bourner M, Weinstein EJ. (2003). Detection of differentially expressed HES-6 gene in metastatic colon carcinoma by combination of suppression subtractive hybridization and cDNA library array. Cancer Lett 198: 229-239. (Pubitemid 37297796)
34. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
35. Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z et al. (2008). Pro-neural transcription factors as cancer markers. BMC Med Genomics 1: 17.
36. Wang GK, Hu L, Fuller GN, Zhang W. (2006). An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 281: 14085-14091. (Pubitemid 43848335)
37. Watson PA, Vinson C, Nesterova A, Reusch JE. (2002). Content and activity of cAMP response element-binding protein regulate platelet-derived growth factor receptor-alpha content in vascular smooth muscles. Endocrinology 143: 2922-2929. (Pubitemid 34809864)
38. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M et al. (2008). Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 27: 918-930. (Pubitemid 351225378)
39. Wu J, Vallenius T, Ovaska K, Westermarck J,Makela TP, Hautaniemi S. (2009). Integrated network analysis platform for protein-protein interactions. Nat Methods 6: 75-77.